Background: A growing number of epidemiological studies indicate that metabolic syndrome (MetS) and its associated features play a key role in the development of certain degenerative brain disorders, including Alzheimer's disease and vascular dementia. Produced by several different medicinal plants, berberine is a bioactive alkaloid with a wide range of pharmacological effects, including antidiabetic effects. However, it is not clear whether berberine could prevent the development of dementia in association with diabetes. Objective: To give an overview of the therapeutic potential of berberine as a treatment for dementia associated with diabetes. Search strategy: Database searches A and B were conducted using PubMed and ScienceDirect. In search A, studies on berberine's antidementia activities were identified using "berberine" and "dementia" as search terms. In search B, recent studies on berberine's effects on diabetes were surveyed using "berberine" and "diabetes" as search terms. Inclusion criteria: Clinical and preclinical studies that investigated berberine's effects associated with MetS and cognitive dysfunction were included. Data extraction and analysis: Data from studies were extracted by one author, and checked by a second; quality assessments were performed independently by two authors. Results: In search A, 61 articles were identified, and 22 original research articles were selected. In search B, 458 articles were identified, of which 101 were deemed relevant and selected. Three duplicates were removed, and a total of 120 articles were reviewed for this study. The results demonstrate that berberine exerts beneficial effects directly in the brain: enhancing cholinergic neurotransmission, improving cerebral blood flow, protecting neurons from inflammation, limiting hyperphosphorylation of tau and facilitating β-amyloid peptide clearance. In addition, evidence is growing that berberine is effective against diabetes and associated disorders, such as atherosclerosis, cardiomyopathy, hypertension, hepatic steatosis, diabetic nephropathy, gut dysbiosis, retinopathy and neuropathy, suggesting indirect benefits for the prevention of dementia. Conclusion: Berberine could impede the development of dementia via multiple mechanisms: preventing brain damages and enhancing cognition directly in the brain, and indirectly through alleviating risk factors such as metabolic dysfunction, and cardiovascular, kidney and liver diseases. This study provided evidence to support the value of berberine in the prevention of dementia associated with MetS.
Introduction
Recent World Health Organization data indicate that the global incidence of diabetes is increasing-approximately 422 million adults were living with diabetes in 2014, compared to 108 million in 1980 [1] . Consequently, the incidences of the various comorbidities linked to diabetes are also on the rise, including degenerative and functional brain disorders, such as Alzheimer's disease (AD) and vascular dementia (VaD) [2, 3] . VaD is a type of dementia associated with cerebrovascular dysfunctions. Type 2 diabetes mellitus (T2DM) is associated with cardiovascular and cerebrovascular disease, and vascular mechanism may underlie the cognitive decline in VaD [4] . AD is a progressive neurodegenerative disorder and the most common form of dementia. Although the etiology of AD is not fully understood, it is generally characterized by deposition of β-amyloid peptide (Aβ) and hyperphosphorylation of tau protein [4] [5] [6] . Aβ reduces both acetylcholine (ACh) uptake and release [7] , and deficient cholinergic neurotransmission is likely to be involved in the AD symptomatology [8] . In fact, most currently available dementia medications are acetylcholinesterase (AChE) inhibitors; however, these drugs only provide relief of symptoms [9] . Importantly, T2DM causes insulin resistance in the brain, and dysfunctional insulin signaling is increasingly recognized in the etiology of AD. Studies have suggested a strong association between insulin signaling and Aβ metabolism [10] . Cerebral insulin resistance results in glycogen synthase kinase 3β (GSK3β) activation, which leads to increased Aβ production and tau phosphorylation [11, 12] , suggesting that dysfunctional insulin signaling or glucose metabolism in the brain could lead to the accumulation of Aβ and hyperphosphorylated tau. Indeed, the term "type 3 diabetes" is often used to characterize AD [13, 14] , given the close pathophysiological link between cerebral insulin resistance and oxidative stress and the histopathological lesions and cognitive impairment observed in AD [7, 8, 15, 16] . Berberine is an isoquinoline alkaloid produced by several medicinal plant species, such as barberry (Berberis vulgaris L.), Indian barberry (B. aristata DC.), goldenseal (Hydrastis canadensis L.), Oregon grape (Mahonia aquifolium (Pursh) Nutt.), Chinese goldthread (Coptis chinensis Franch., C. japonica Makino., and C. teeta Wall.) and Amur cork tree (Phellodendron amurense Rupr.). Berberine-containing plants have historically been used to treat gastrointestinal complications such as diarrhea and dysentery [17, 18] , and berberine's antimicrobial activity has been wellcharacterized [17, 19] . However, in recent years, the focus of berberine research has shifted towards potential therapeutic benefits in treating metabolic dysfunctions, such as T2DM, with data indicating glucose-and lipid-lowering effects [20, 21] . Clinical evidence suggests that berberine significantly reduces fasting and postprandial plasma glucose, glycosylated hemoglobin A1c, serum cholesterol, triglycerides and low-density lipoprotein cholesterol (LDL-C) in T2DM patients [22, 23] . Therapeutic benefits of berberine in treating T2DM and metabolic syndrome (MetS) have been reviewed previously [20, 21, 24] . In addition, preclinical evidence suggests that berberine has neuroprotective activities [25, 26] . However, there is no comprehensive review to discuss the potential use of berberine as a treatment for dementia associated with metabolic dysfunctions. This paper reviews the current preclinical and clinical data on the effects of berberine, particularly focusing on cognitive dysfunctions associated with T2DM and its associated comorbidities, and discusses potential benefits and underlying mechanisms at the molecular level.
Methods
In order to perform a systematic review of studies reporting the effects of berberine on cognitive dysfunctions and diabetes, two searches (A and B) were conducted using PubMed (https://www.ncbi.nlm.nih.gov/pubmed) and ScienceDirect (https://www.sciencedirect.com/).
Information sources and Search strategy 2.1.1. Search A: berberine for dementia prevention
Studies of berberine's effects on dementia were retrieved using the search terms "(berberine) AND (dementia)" in PubMed's and ScienceDirect's advanced search interfaces, returning articles between January 2000 and May 2019.
Search B: berberine for diabetes intervention
To compile the currently available data on the effectiveness of berberine on diabetes and its comorbidities, advanced searches of PubMed and ScienceDirect databases were conducted, matching the search terms "(berberine) AND (diabetes)" in title, abstract and keywords. Articles published between January 2010 and May 2019 were included in the search.
Study selection and data extraction
Initially, studies were screened for relevance based on the title and abstract. At this point, reviews, unrelated studies and works without available full text were excluded. The full texts of potential studies were assessed following the exclusion and inclusion criteria listed below. Eligibility criteria: (1) articles published in any non-English language were excluded; (2) case reports were excluded; (3) studies using mixtures of several compounds, conjugates and crude extracts were excluded; (4) original studies in vivo, in vitro and clinical studies were included. The quality of included articles was evaluated by assessing the intervention methods, materials (including the source of berberine) and the usage of established experimental systems and protocols. The following data were extracted: publishing data, research question(s), study design, outcomes and conclusion. Data were extracted by one author, checked by a second; and quality assessments by two other authors were independently conducted.
Synthesis of results
Included reports were classified according to the major research questions (i.e., antidementia, antidiabetic, or comorbidities). Results were synthesized, focusing on the association between dementia and MetS. Meta-analysis was not appropriate, due to the highly variable research methodologies and outcome measures.
Results
Database searches A and B identified research articles that addressed the therapeutic effects of berberine on dementia and diabetes, respectively. From search A, 65 articles (61 in PubMed and 4 in ScienceDirect) were identified, and 22 articles were deemed appropriate for inclusion according to the selection criteria. Among those, 16 studies used nondiabetic models [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (Table 1 ) and 6 studies used diabetic models ( Table 2) . From search B, 458 (372 articles in PubMed and 86 articles in ScienceDirect) were identified and 101 articles met the selection criteria, of which 4 articles were in both A and B. Seven additional studies on diabetes-associated dementia were determined to be relevant. One article [43] was classified into both "studies used diabetic models" ( Table 2) and "diabetes-associated dementia" (Tables 3-10); as it was relevant to both sections, a total of 13 articles were finally in Table 2 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and 91 articles in Tables 3-10 [22, 43, . Tables 3-10 are categorized by eight groups according to the main topics of each study: (1) pancreatic Attenuated CCH-induced spatial learning and memory deficit; reduced CCH-induced apoptosis in hippocampal CA1 and increased neuronal density.
Berberine protects the hippocampus against CCH, thus may be suggested for VaD. [27] Hussien HM (2018)
Heavy metalinduced AD In vivo: protected learning and memory; reduced lipid peroxidation and NO; increased antioxidant levels (GSH, SOD, GST, and GPx); reduced serum and brain AChE and MAO; reduced serum inflammatory cytokines (TNF-, IL-1, IL-6, and IL-12); reduction of APP and tau in the brain; protected against neurodegeneration in hippocampal CA1. In silico: may inhibit AChE, COX-2 and TACE.
Berberine has beneficial effect for AD via anti-inflammatory/antioxidant mechanism.
[28]
He W (2017) Familial AD In vivo: APP/PS1 AD model mice Berberine 50 or 100 mg/(kgd) for 14 d (p.o.)
Mitigated cognitive impairment; inhibited tau phosphorylation in the hippocampus; reduced the expression of NF-B elements in the hippocampus; enhanced GSH antioxidant; reduced lipid peroxidation; inhibited neuroinflammation (CD45, GFAP, IL-1, TNF-).
Berberine attenuated cognitive deficits and limited tau hyperphosphorylation, possibly via NF-κB pathway inhibition, and reduction of oxidative stress and neuroinflammation.
[ 35] Kim YJ (2017) Cholinergic signaling impairment
In vitro: AChE inhibition Berberine 2 µmol/L 80% AChE activity inhibition. Berberine may enhance cholinergic neurotransmission via enhancement of acetylcholine level.
[36]
Sadeghnia HR (2017) Recovered recognition memory; prevented ROS generation and lipid peroxidation in the hippocampus; reduced protein carbonylation in the hippocampus and cerebral cortex; prevented reduction of aminolevulinic acid dehydratase activity (heme synthesis) in the cerebral cortex; prevented the reduction of antioxidants in the hippocampus and cerebral cortex.
Glutamine-induced neurotoxicity
Berberine is neuroprotective and preserves recognition memory via reduction of oxidative stress.
[48]
Yin S (2018) VaD
In vivo: STZ-induced VaD model in rats; in vitro: cultured endothelial cells treated with HG
In vivo: berberine 1.0 g/(kgd) for 8 weeks (p.o.)
In vivo: improved short-term learning and memory and alleviated the impairment of spatial memory; increased posterior cerebral artery blood flow; suppressed hyperglycemia-induced ectopic expression of miR-133a in cerebral middle artery; upregulated GTPCH1 expression and BH4 in cerebral middle artery and serum NO; suppressed serum MDA. In vitro: suppressed HGinduced miR-133a expression; recovered BH4 levels and NO generation.
Berberine alleviates cognitive impairment in diabetic mice via improving endothelial NO generation and cerebral blood flow.
[44]
Li Reduced cognitive impairment; promoted lipid metabolism (lowered body weight, reduced TAG, TC and LDL-C); decreased fasting glucose (better insulin tolerance); protected hippocampal neurons and synapses; inhibited hippocampal inflammation (NF-κB, TNF-); reduced ER stress.
Berberine is protective against DE-induced dementia, possibly by reducing inflammation and ER stress.
[49]
Sandeep MS (2017)
Dysfunctional glucose metabolism in the brain associated with diabetes
In vivo: STZ-induced diabetic model in rats
Restored body weight and improved blood and urine sugar levels; restored brain weight; restored GLUT1 and GLUT3 levels in the brain; restored insulin signaling molecules (IRS, phospho-PI3K and phospho-Akt1) in the brain.
Berberine modulates glucose metabolism in the brain, which may contribute to neuroprotection.
[50]
Chen Q (2017) Berberine's effects in medial prefrontal cortex (mPFC) of diabetic model: did not change IR expression; suppressed upregulation of phosho-IRS; inhibited phospho-PI3K, phospho-Akt and phospho-GSK3β; suppressed NF-kB activation, and phospho-JNK, PKC, IL-18, IL-1β and TNF-α induction; upregulated GLUT3 and enhanced glucose-uptake in the brain; suppressed diabetesinduced APP and Aβ formation; suppressed diabetes-induced BACE-1 upregulation; ameliorated fear memory deficit in diabetic rats.
Cognitive dysfunction associated with diabetes
Berberine inhibits inflammation and APP and Aβ formation in mPFC, thereby preventing cognitive dysfunction, possibly via inhibition of PI3K/Akt/GSK3β pathway, JNK, NF-kB and PKC. Berberine is superior in brain protection than Met. Berberine suppressed diabetes-induced reactive gliosis in the hippocampus possibly via suppression of oxidative stress.
[53]
Chatuphonpr asert W (2014)
Oxidative stress in the brain Reduced oxidative stress (MDA levels) in the brain; improved catalase activity in the brain. Berberine may alleviate oxidative stress in the brain.
[43]
Moghaddam HK (2013)
Learning and memory impairments
In vivo: STZ-induced diabetes in rats Berberine 50 and 100 mg/(kgd) for 12 weeks (p.o.)
Berberine improved short-term plasticity in the dentate gyrus of hippocampus. Berberine prevents diabetes-induced learning and memory defects by improving hippocampal plasticity.
[54]
Kalalian-Moghaddam H (2013)
In vivo: STZ-induced diabetes in rats Berberine 100 mg/(kgd) for 11 weeks (p.o.)
Restored hippocampal synaptic plasticity (LTP); ameliorated learning and memory impairment; attenuated apoptosis of hippocampal CA1 neurons.
Berberine prevents diabetes-induced learning and memory defects by improving hippocampal LTP via inhibiting neuronal death.
[55]
Hsu YY (2013)
Glucose-induced neurotoxicity
In vitro: HG-induced damage in neuronal cells (SH-SY5Y) Berberine 1, 3 and 10 µmol/L Inhibited HG-induced apoptosis of neurons; inhibited HG-induced ROS generation; increased Bcl-2; reduced HG-induced cytochrome c release; induced IGF-1 receptor; induced phosphorylation of Akt and GSK3; induced nuclear factor erythroid 2 and heme oxygenase-1 expression; restored NGF levels.
Berberine protects neurons from HG-induced oxidative stress and death, possibly via IGF-1/Akt/GSK3 signaling, Nrf2 activation, and NGF induction.
[47]
Bhutada P (2011)
Memory dysfunction associated with diabetes
In vivo: STZ-induced diabetic model in rats Berberine is effective against diabetes via restoration of glucose-stimulated insulin release from β-cells.
[56]
Chandirasegaran G (2017)
Pancreatic dysfunction
In vivo: STZ-induced diabetic model in rats Reduced blood glucose and HbA1c; restored plasma insulin and hemoglobin; suppressed lipid peroxidation and restored antioxidants; reduced pancreatic damage; reduced inflammatory mediators and increased antiapoptotic and anti-inflammatory factors.
Berberine is anti-hyperglycemic and pancreas-protective possibly via antioxidative and anti-inflammatory activities.
[140]
Chen DL (2017) Pancreatic dysfunction
In vivo: STZ-induced diabetic model in mice; in vitro: β cell line (NIT-1) exposed to HG Berberine 5mg/(kgd) for 3 weeks (i.p.)
In vivo: suppressed serum glucose, TC, TAG and MDA and restored insulin and SOD; suppressed miR-106b and restored SIRT1 in islets. In vitro: suppressed HG-induced MDA and restored insulin and SOD; suppressed HG-induced miR-106b and restored SIRT1.
Berberine restores insulin and suppresses hyperglycemia possibly via modulating miR-106b/SIRT1 pathway in pancreatic islets.
[141]
Liu L (2014) HG-induced oxidative stress in pancreatic islets
In vitro: insulinoma cell line (INS-1E) and pancreatic islets isolated from rat and mouse
In vitro: berberine 5 µmol/L Berberine's effects in INS-1E exposed to HG: restored antioxidant (SOD); attenuated nitrosative stress (nitrotyrosine); restored phospho-AMPK; restored UCP2 expression; reduced mitochondrial ROS via AMPK signaling and restoration of UCP2; restored glucose-stimulated insulin secretion via AMPK signaling and restoration of UCP2. Berberine's effects in isolated islets: restored phosho-AMPK in rats and mice; suppressed nitrosative stress via UCP2, and induced SOD in rats and db/db mice; restored insulin secretion via UCP2 in rats and db/db mice.
Berberine inhibited oxidative and nitrosative stress and restored insulin secretion in HGexposed islets via activation of AMPK and UCP2. [142] Shen N (2012) Pancreatic dysfunction
In vitro: mouse β-cell line (NIT-1) exposed to HG; in vivo: HFDinduced obesity in mice
In vitro: berberine 1 µmol/L; in vivo: berberine 50 mg/(kgd) for 10 weeks (p.o.)
In vitro: suppressed HG-induced insulin gene expression in β-cells via AMPK activation. In vivo: improved insulin resistance and glucose tolerance; decreased insulin in pancreatic islets.
Berberine may prevent diabetes by inhibiting insulin expression in β-cells via AMPK activation.
[139]
Chueh WH (2012) Pancreatic dysfunction
In vitro: STZ-treated primary pancreatic islet cells from mice
In vitro: berberine 1 and 3 µmol/L Reduced cell death; pre-treatment can reduce the increase in Bax/Bcl-2 gene expression ratio.
Berberine may protect pancreatic islets via decreasing Bax/Bcl-2 ratio thereby inhibiting apoptosis.
[138]
Chueh WH (2011) Pancreatic dysfunction In vitro: induced FGF21 expression in brown adipocytes; induced Bmal1 expression in brown and beige adipocytes; enhanced AMPK phosphorylation. In vivo: restored Fgf21 mRNA expression in BAT, which was reduced by HFD; reduced body weight under HFD.
Berberine may induce adipocyte browning by inducing FGF21 via AMPK signaling and modulate Bmal1 (molecular clock), which may contribute to high energy consumption in BAT, thereby suppressing HFD-induced obesity. Clinical: berberine has no additional benefit to standard therapy. In vitro: berberine alone alleviates ox-LDL-induced inflammatory responses via Gal-3 down-regulation, AMPK activation and NF-B inhibition in macrophages.
[135]
Paul M (2019)
Platelet hyperreactivity
In vitro: human platelets thrombin-and collagen-induced aggregation model, exposed to HG Berberine 25 and 50 µmol/L Inhibited HG-potentiated platelet aggregation; inhibited mitochondrial membrane potential depolarization, ROS generation in HG-treated platelets, cardiolipin peroxidation, and restored cell viability; inhibited HG-induced ERK, pI3K, p38 and p53 phosphorylation, cytochrome c release, MPTP, and caspase-3 activation; inhibited glutathione reductase, aldose reductase and NOX; inhibited thrombin-induced ATP release.
Berberine attenuates HG-primed platelet aggregation, possibly via attenuation of ROS-mediated p38-p53 activation and platelet apoptosis.
[134]
Hang W (2018)
Cardiomyocyte hypertrophy
In vitro: HG-induced hyperglycemia and cardiomyocyte hypertrophy model in H9C2 cell line Berberine 100 nmol/L Attenuated HG-induced hypertrophy; protected mitochondria from HG-induced dysfunction (reduced ATP generation and MMP disruption); restored balance of mitochondrial fission/fusion; restored PGC-1α expression, mitogenesis and mitochondrial content; suppressed HG-induced mitophagy and mTOR activity; restored LC3 and Beclin 1 expression and phospho-AMPK.
Berberine ameliorates HG-induced cardiomyocyte injury via restoring AMPK signaling, mitochondrial function and autophagy.
[132]
Hu M (2018)
HFD-induced metabolic dysfunction.
In vivo: HFD-induced metabolic dysfunction in mice Berberine is anti-atherosclerotic (possibly via altered gut microbiota compositions).
[130]
Li G (2018)
Diabetic cardiac fibrosis
In vivo: STZ and HFD-induced type 2 diabetic model in rats; in vitro: cardiac fibroblasts exposed to HG Long-term berberine treatment ameliorates cardiac fibrosis by downregulating IGF-1R expression, and MMPs, α-SMA and collagen type I in diabetic heart.
[129]
Wang L (2018)
Insulin resistance associated with obesity
In vivo: HFD-induced insulin resistance in mice; in vitro: SVF Berberine alleviates atherosclerosis via inhibiting inflammation in the arterial tissues.
[74]
Chang W (2017)
Heart diseases
In vitro: cardiac myocytes (H9c2) Berberine 6.25-25 µmol/L Inhibited oxygen consumption and DNA synthesis; reduced cardiolipin synthesis from oleic acid and increased cardiolipin synthesis from palmitic acid; inhibited PKCδ activation.
Berberine inhibits the growth of cardiomyocytes and oxygen consumption and altered cardiolipin metabolism, possibly via PKCδ inhibition.
[127]
Ma YG (2017)
Hypertension
In vivo: STZ-induced diabetic model in rats Berberine helps control hyperglycemia and hypertension in diabetes, possibly via restoring ion channel activities [126] Li H (2016)
Atherosclerotic plaque instability
In vivo: HHCY model, ApoE -/mice fed with HTL; ex vivo: HTLexposure of organ culture of aortic ring isolated from the descending aorta of mice; in vitro: HUVECs exposed to HTL Restored body weight and improved blood glucose, HbA1c, TC, TAG, HDL-C, and LDL-C; protected myocardium, as well as other tissues (pancreas, liver, and kidney).
Berberine produces myocardial salvaging effects in diabetes.
[124]
Ma YG (2016)
Vascular dysfunction
In vivo: HFD and STZ-induced diabetic model in rats; in vitro: cerebral VSMCs Berberine 100 mg/(kgd) for 8 weeks (p.o.)
In vivo & in vitro: restored body weight, and reduced blood glucose and insulin; inhibited the contractile response of VSMCs; inhibited Ltype Ca 2+ channel current.
Berberine alleviates the cerebral arterial contractility induced by diabetes via regulating intracellular Ca 2+ levels in smooth muscle cells.
[123]
Geng FH (2016)
Vascular insulin sensitivity associated with diabetes
In vivo: STZ and HFD-induced diabetic model in rats; ex vivo: mesenteric artery rings isolated from control and diabetic mice; in vitro: human artery endothelial cell line (EA.hy926), exposed to HG and palmitate Berberine improves vascular functions by protecting endothelial cells from HG/HF-induced stress via AMPK and Akt signaling, which were mediated by IR signaling.
[121]
Chang W (2016a)
Ischemia-reperfusion injury in T2DM
In vivo: ischemia-reperfusion in STZ and HFD-induced diabetic model in rat.
Berberine 100 mg/(kgd) for 7 d before heart perfusion
Berberine pretreatment: reduced TAG, TC and MDA, but did not alter blood glucose and SOD levels; reduced arrhythmias; increased the ratio of AMP/ATP and ADP/ATP; increased AMPK activity, as well as phospho-Akt and phospho-GSK3β.
Berberine is cardioprotective via activation of AMPK and Akt and inactivation of GSK3β.
[120]
Chang W (2016b) Berberine suppresses arrhythmia in diabetes via restoration of K + channel expression. In vitro: reduced mitochondrial membrane potential; reduced SIRT3 expression; inhibited oxygen consumption rate (complex I activity) in WT cells, but not in Sirt3 -/cells; enhanced glucose uptake and glycolysis and inhibited glucagoninduced gluconeogenesis; increased AMP and decreased cAMP as effectively as nicotinamide (SIRT3 inhibitor) in WT cells, but not in Sirt3 -/-; suppressed glucagon-induced PKA phosphorylation. In vivo: enhanced glucose and pyruvate tolerance; inhibited glucagon-induced glucose generation.
Insulin resistance of cardiomyocytes
Berberine promotes glucose uptake and inhibits gluconeogenesis via SIRT3 inhibition.
[109]
Liu D (2018) Fatty liver disease Reduced liver triglyceride; induced autophagy in the liver; induced FGF21; increased oxygen consumption, energy expenditure and the expression of brown-like genes (UCP1, DIO2, PRDM16) in the liver.
Berberine regulates lipid utilization and energy metabolism in the liver via autophagy, FGF21 signaling activation, and brown-like gene induction.
[106]
Wei S (2016) Hyperglycemia and hyperlipidemia
In vivo: STZ and HFDinduced diabetic model in mice; in vitro: HepG2 cells exposed to palmitate Reduced HFD-induced weight gain and HFD-induced insulin, and enhanced oral glucose tolerance; increased unsaturated fatty acids in the liver; protected hepatic mitochondria from HFD-induced dysfunctions (membrane potential, oxidative phosphorylation and ATP generation).
Berberine protects liver mitochondria from HFD-induced dysfunctions.
[101]
Lao-ong T (2012) Oxidative stress in the liver Restored catalase, SOD, GPx and GSH in the serum and the liver; reduced MDA in the serum and the liver; restored cyclin-dependent kinase 9 and cyclin T1 expression in the liver.
Berberine protects the liver by inducing antioxidants via upregulation of P-TEFb.
[97]
Liu X (2010) Hepatic insulin In vivo: HFD and STZ-Berberine 150 Improved oral glucose tolerance; alleviated liver weight increase; reduced blood Berberine protects the liver via modulating metabolic [95] resistance induced T2DM model in hamster mg/(kgd) for 9 weeks (p.o.) glucose, serum insulin, TC, TAG, FFA, and LDL-C; reduced the expression of SREBPs and target genes and restored the expression of LXR and PPAR, as well as their target genes in the liver.
regulators such as LXR, SREBPs, and PPAR in the liver, thereby improving hepatic glucose utilization and lipid metabolism. AChE: acetylcholinesterase; AChR: acetylcholinesterase receptor; AMPK: 5'-adenosine monophosphate-activated protein kinase; FBG: fasting blood glucose; FFA: free fatty acid; FGF21: fibroblast growth factor 21; FINS: fasting insulin; GPx: glutathione peroxidase; GSH: reduced glutathione; GSK3: glycogen synthase kinase 3 ; GSSG: oxidized glutathione; HDL-C: high-density lipoprotein cholesterol; HFD: high-fat diet; HFHS: high fat and high sucrose; HNF-4: hepatocyte nuclear factor 4; IL: interleukin; i.p.: intraperitoneal injection; IR: insulin receptor; IRS: insulin receptor substrate; LDL-C: low-density lipoprotein cholesterol; LKB1: liver kinase B1; LPS: lipopolysaccharide; LXR: liver X receptor; MDA: malonaldehyde; NAFLD: non-alcoholic fatty liver disease; NF-κB: nuclear factor κB; P-TEFb: positive transcription elongation factor b; PKA: protein kinase A; p.o.: per os; PPAR: peroxisome proliferator-activated receptor; SIRT: sirtuin; SOD: superoxide dismutase; SREBP: sterol regulatory element-binding protein; STZ: streptozotocin; T2DM: type 2 diabetes mellitus; TAG: triacylglycerol; TC: total cholesterol; TLR-4: toll-like receptor 4; TNF-α: tumor necrosis factor-α; TORC2: target of rapamycin complex-2; WT: wildtype. Berberine protects the function of podocytes via inhibition of TGF-β signaling from GMCs.
[94]
Li Z (2017) Diabetic nephropathy (glomerular hypertrophy)
In vivo: STZ-induced diabetic nephropathy model in rats
Berberine 400 mg/(kgd) for 12 weeks.
Alleviated glomerular hypertrophy and mesangial matrix expansion; suppressed TGF-β, α-SMA, vimentin and NF-B in the kidneys.
Berberine inhibits renal fibrosis associated with diabetes via suppression of TGF-β and NF-B signaling.
[93]
Jin Y (2017) Diabetic nephropathy (podocytes damage)
In vitro: HG-induced podocyte (MPC5) injury model In vivo, berberine's effects in diabetic model: reduced blood glucose, kidney/body weight ratio, urine total protein and creatinine ratio (UTP/C), BUN, SCr; ameliorated renal pathology; reduced PGE2 and EP1 expression. In vitro, berberine's effects in HG-exposed GMCs: reduced PGE2-EP1 signaling; suppressed GMCs proliferation.
Berberine is renoprotective, possibly via inhibition of PGE2-EP1-Ca 2+ signaling in GMCs. Reduced FBG, triglyceride, TC and LDL-C levels in diabetic rats; ameliorated kidney hypertrophy and inflammation; reduced type IV collagen and TGF- expression in the kidneys; improved renal functions (reduced BUN, SCr, urine microalbumin/creatinine, and urine protein/creatinine); restored G protein-coupled receptor kinase (GRK) expression patterns and cAMP levels in renal cortex.
Berberine exerts renoprotection in diabetes possibly via modulating G protein-adenylate cyclase-cAMP signaling pathway.
[82]
Lan T (2012) Mesangial hypertrophy
In vitro: GMCs isolated from rats, exposed to HG Berberine 30 and 90 µmol/L Inhibited HG-induced mesangial hypertrophy and -SMA formation; suppressed HG-induced TGF- and FN expression; inhibited HG-induced SphK1 activation; suppressed HG-induced AP-1 activation.
Berberine protects against mesangial hypertrophy by suppressing TGF- and SphK1/AP-1 pathways.
[80]
Huang K (2012)
Renal fibrosis
In vitro: GMCs isolated from rats, exposed to HG; in vivo: STZinduced diabetes in rats In vitro: reduced HG-induced SphK1-sphingosine 1-phosphate (S1P2) receptor expression in GMCs; suppressed S1P2 receptor-mediated FN expression under HG; inhibited HG-induced NF-B activation.In vivo: reduced diabetes-induced S1P2 receptor expression in the kidneys; reduced FN expression in the kidneys.
Berberine suppresses diabetic renal fibrosis via inhibiting NF-B activation and downregulating S1P2 receptor expression. Berberine exerts renoprotective effects via inhibiting oxidative stress and restoring podocytes survival.
[79]
Lan T (2010) Renal hypertrophy
Alloxan-induced diabetic model in mice
In vivo: berberine 300 mg/(kgd) for 12 weeks (p.o.)
Reduced FBG, kidney/body weight ratio, BUN, SCr and 24 h albuminuria; prevented renal hypertrophy, TGF- upregulation, and FN and collagen IV accumulation; downregulated SphK and S1P expression.
Berberine prevents renal hypertrophy via inhibiting SphK-S1P signaling. Berberine modulates gut microbiota, specifically increases the abundance of Akkermansia, which may contribute to metabolic protection.
Liu D (2018) Berberine restores balance in gut microbiota.
Gut dysbiosis associated with FLD
[73]
Zhang Q (2014)
Intestinal glucose and lipid metabolism
In vivo: STZ and HFD-induced diabetic model in rats Berberine improves blood glucose levels, possibly via GnRH-GLP-1 pathway in the ileum.
[72]
Shan CY (2013)
Intestinal barrier dysfunctions
In vivo: HFD and STZ-induced diabetes in rats Berberine treatment augments GLP2 secretion and restores intestinal functions in T2DM.
[71]
Zhang X (2012)
Gut microbial dysbiosis associated with obesity and metabolic disorders
In vivo: HFD-induced obesity and insulin resistance in rats Berberine 100 mg/(kgd) for 18 weeks (p.o.)
Prevented obesity and improved insulin sensitivity; prevented systemic inflammation; reduced the bacterial diversity of the gut microbiota; reduced total bacterial population under HFD; enriched Allobaculum and Blautia (SCFA producers); increased fecal SCFA levels.
Berberine prevents HFD-induced obesity and insulin resistance at least partly via enriching SCFA-producing gut microbiota.
[70]
Li ZQ (2012)
Intestinal glucose uptake
In vivo: postmaltose (in rats and dogs) and postglucose blood glucose (in rats); insulin sensitivity test in rats. In vitro: maltose digestion and glucose transport by enterocytes (Caco-2); -glycosidase inhibition assay
In vivo: rats, berberine 500 mg/kg (p.o.); dogs, 80 mg/kg, 1 h before tests.In vitro: Berberine 250 mg/L In vivo: delayed postmaltose blood glucose in rats and dogs; did not affect postglucose blood glucose in rats; had no effect on insulin levels. In vitro: inhibited maltose digestion by Caco-2 cells; inhibited -glycosidase activity.
Berberine acutely inhibits digestion of maltose in the intestine.
[69]
Liu L (2010)
Intestinal disaccharide metabolism
In vivo: STZ-induced diabetic model in rats; in vitro: intestinal epithelial cells (Caco-2)
In vivo: berberine 100 and 200 mg/(kgd) for 5 weeks (p.o.); in vitro: berberine 10 and 50 µmol/L
In vivo: reduced food intake and blood glucose and restored serum insulin level; decreased sucrase and maltase activity and SI complex expression in the small intestine; reduced blood glucose after oral sucrose or maltose administration. In vitro: inhibited sucrase and maltase activity, which was suppressed by H-89 (PKA inhibitor); inhibited SI complex mRNA expression.
Berberine suppresses disaccharidase activity and SI complex mRNA expression, which has beneficial metabolic effects. The effect involves PKA-dependent pathway. Berberine may protect Müller cells from HG-induced apoptosis via activation of AMPK signaling, suppression of mTOR and induction of autophagy.
[66]
Fu D (2016)
Diabetic retinopathy
In vitro: human Müller cell exposed to HOG-LDL vs native-LDL Berberine may prevent diabetic retinopathy via protection of retinal endothelial cells and inhibiting HGinduced leukocyte activation.
[64]
AMPK: 5'-adenosine monophosphate-activated protein kinase; GPx: glutathione peroxidase; HG: high glucose; HOG: highly oxidized; glycated; LDL: low-density lipoprotein; mTOR: mammalian target of rapamycin; NF-κB: nuclear factor κB; ROS: reactive oxygen species; SOD: superoxide dismutase. In vivo: STZ-induced diabetic model in rats; in vitro: HG-exposed in N2a cells
In vivo: berberine 50 and 100 mg/(kgd) for 2 weeks (p.o.); in vitro: berberine 5 and 10 µmol/L
In vivo: reduced plasma glucose and MDA, and increased GSH; ameliorated motor and sensory dysfunctions; reduced DNA fragmentation in sciatic nerve; restored phospho-AMPK and ATP levels; reduced IL-6 and TNF-α in sciatic nerves; restored the levels of antioxidative stress proteins and mitochondrial biogenesis-related proteins. In vitro, berberine's effects in HG-exposed neurons: induced mitochondrial biogenesis and restored membrane potential; restored phospho-AMPK and Nrf2 levels.
Berberine activates AMPK. Berberine alleviates neurotoxicity in diabetes, possibly via protecting mitochondria and restoring Nrf2-mediated endogenous antioxidant system. Reduced FBG, HbA1c, TAG and TC; restored somatosensory transmission; protected hippocampal CA1 neurons; restored neuritin expression; downregulated phosphorylation of p38 and JNK, but not ERK in the hippocampus.
Berberine has a beneficial effect against diabetic neuropathy possibly via neuritin expression and inhibition of p38 and JNK pathways.
[62]
Kim SO (2013)
Diabetic neuropathy
In vivo: STZ-induced diabetes in rats Berberine 10 and 20 mg/kg for 1 or 2 weeks (i.p.)
Single and two-week administration of berberine exhibited anti-allodynic effects. Berberine could be anti-allodynic possibly via anti-inflammatory or antidepressant capacity. Berberine reduced blood glucose, cholesterol, TAG, LDL-C, HbA1c, insulin resistance and methylglyoxal.
Berberine is effective in treating T2DM. Berberine is more effective than metformin.
[60]
Dong Y (2016) Metabolic dysfunctions associated with T2DM
In vivo: T2DM model using Zucker diabetic fatty rats (fa/fa) fed with HFD Berberine 300mg/(kgd) for 12 weeks (p.o.)
In vivo: reduced serum HbA1C, insulin, TC and TAG; restored the glyoxylate and dicarboxylate metabolism, pentose and glucuronate interconversions and sphingolipid metabolism.
Berberine is antidiabetic via restoration of glycometabolism and lipometabolism. Reduced body and liver weight gain, FBG, insulin, and serum lipid (TC, TAG, and LDL-C) levels; reduced oxidative stress (reduced plasma MDA and increased plasma SOD); reduced apolipoprotein B and increased apolipoprotein A1 levels; induced GLUT4 in the skeletal muscle and LDL receptor in the liver.
Berberine is effective against hyperglycemia and hyperlipidemia and reduces oxidative stress, possibly via enhancing glucose consumption in the muscle and lipid metabolism in the liver.
[59]
Xu M (2014) Hyperglycemia
In vitro: hepatocytes (HepG2) and myoblasts (C2C12)
Berberine 20 µmol/L Inhibited mitochondrial complex I and reduced ATP synthesis in myoblasts; increased glucose consumption and lactate release in both hepatocytes and myoblasts; enhanced AMPK and acetyl coenzyme A synthetase phosphorylation, and AMPK inhibition.
Berberine enhances glucose consumption possibly via shifting cellular metabolism from mitochondrial oxidative phosphorylation to glycolysis, independently of AMPK signaling.
[57]
Yang TC (2014)
Glucose uptake by skeletal muscles Reduced blood glucose and improved OGTT; reduced food intake; did not change plasma insulin levels; did not change SOD, MDA or GSH in the liver.
Berberine is hypoglycemic via unknown mechanism.
[78]
Chen C (2010) Glucose uptake In vitro: adipocytes (3T3-L1) and myocytes (L6); in vivo: HFDinduced obesity and leptin receptor deficient (db/db) mice
In vitro: berberine 1.25-20 µmol/L; in vivo: berberine 100 mg/(kgd) for 2 weeks (p.o.)
In vitro: promoted glucose uptake by 3T3-L1 and L6 cells; inhibited PTP1B and increased IR phosphorylation; increased insulin signaling (phospho-IRS, phosphor-Akt). In vivo: reduced blood glucose; did not increase plasma insulin level and insulin synthesis in pancreas; activated insulin signaling.
Berberine mimics insulin action via inhibition of PTP1B activity.
[100]
Ma X (2010) Glucose transport in skeletal muscles
In vitro: skeletal muscles isolated from rats Berberine 0.3 mmol/L Induced AMPK phosphorylation and increased AMPK activity; stimulated glucose transport in the absence of insulin; increased AS160 phosphorylation (downstream of AMPK); decreased PCr content.
Berberine reduces the intracellular energy status and acutely stimulates AMPK and insulin-independent glucose transport in skeletal muscle. Berberine lowers blood glucose in T2DM through upregulation of IR. Tables 1 and 2 shows 25 studies that suggested direct neuroprotective and cognition-enhancing effects of berberine. Potential benefits were demonstrated in 16 nondiabetic studies (Table 1 ) and in 9 studies using diabetic models ( Table 2 ). In nondiabetic models, berberine protected learning and memory in heavy metal-induced AD [28] , Aβ-induced memory deficits model [34] , familial AD models [29, 35, 38] and D-galactose-induced brain damage [40, 145] . In the rat VaD model induced by chronic cerebral hypoperfusion, berberine protected hippocampal calyculin A1 (CA1) neurons and prevented memory deficit [27] . Mechanistically, berberine reduced oxidative stress in the brain by increasing the levels of antioxidants, including glutathione, glutathione peroxidase and superoxide dismutase (SOD) [28, 35, 37] , reduced AChE expression levels [28] and AChE activity at as low as 0.44-6 µmol/L half maximal inhibitory concentration [30, 33, 36, 41] and uncompetitively inhibited indoleamine 2,3-dioxygenase [32] , the first rate-limiting enzyme of kynurenine pathway, thereby potentially reducing the accumulation of neurotoxic metabolites involved in AD pathogenesis [146] [147] [148] . Berberine reduced Aβ generation in Swedish mutant amyloid precursor (APP)-expressing cells [31] and suppressed the Aβ-induced inflammatory response in microglia [42] . In addition, berberine reduced hyperphosphorylation of tau and APP [29, 39] , possibly through inactivation of GSK3β via Akt signaling [29] . On the other hand, growing evidence suggests that berberine prevents dementia associated with diabetes [43-55,61-63] ( Table 2 ). Berberine inhibited apoptosis in the hippocampus and cerebral cortex, suppressed anxiety and restored recognition memory in the sporadic AD model induced by intracerebroventricular injection of streptozotocin (STZ), possibly via reduction of AChE activity [44, 51] . It also suppressed hippocampal inflammation, protected neurons and synapses and ameliorated cognitive impairment through improved lipid metabolism in leptin receptor-deficient (db/db) diabetic mice [49] . In STZ-induced diabetic model, berberine alleviated cognitive dysfunctions [44, 45, 49, 53, 55, 62] by protecting hippocampal CA1 neurons [55, 62] and restoring hippocampal short-term and long-term plasticity [54, 55] , reducing oxidative stress [55] , inhibiting brain inflammation [51, 53] , suppressing Aβ generation via inhibition of the phosphoinositide 3kinase (PI3K)/Akt/GSK3β pathway [51] and reducing diabetes-associated AChE induction in the hippocampus and cortex [45] . In the STZ-induced VaD model in rats, berberine enhanced nitric oxide (NO) generation and blood flow in the cerebral artery, reduced oxidative stress and alleviated memory impairment, possibly via suppression of hyperglycemia-induced ectopic expression of miR-133a [44] . Of note, berberine supplementation restored glucose transporter levels and insulin signaling in the brain [50] , suggesting that modulation of glucose metabolism in the brain may underlie the neuroprotective effect of berberine. Moreover, berberine activated 5'-adenosine monophosphate-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis, restored mitochondrial membrane potential in neurons under high glucose (HG) stress [63] and protected neurons from glucose-induced oxidative stress in vitro [37, 47] , suggesting that berberine could alleviate neuronal damages under hyperglycemia.
Antidementia

Prevention of MetS 3.2.1. Pancreatic dysfunction
Both clinical and preclinical studies ( Table 3 ) have shown that berberine could alleviate insulin resistance and reduce blood glucose [60, 72, 75, 124, 139, 140] , which is likely due to the protection of pancreatic β-cells [56, 137, 140] and restoration of insulin secretion [56, 139, 142] . Molecular mechanisms underlying berberine's pancreatic protection include modulation of anti-apoptotic Bax and pro-apoptotic Bcl-2 expression levels [138] , activation of AMPK [139, 142] , restoration of sirtuin 1 (SIRT1) [141] and induction of uncoupling protein 2 (UCP2) [142] . SIRT1 is a nicotinamide adenine dinucleotide + -dependent histone deacetylase that plays crucial roles in the protection of pancreatic β-cells against inflammation and oxidative stress [149] ; UCP2 regulates redox homeostasis and insulin expression in β-cells. Thus, it is likely that berberine promotes the survival of β-cells through several molecular pathways.
Vascular dysfunction
In STZ-induced diabetic models (Table 4 ), berberine reduced total cholesterol, triglyceride and LDL-C, while increasing high-density lipoprotein cholesterol (HDL-C) [58, 59, 62, 75, 105, 108, 120, 129, 141] . In ApoE -/mice fed with high-fat diet (HFD), a model for Western diet-induced atherosclerosis, berberine significantly attenuated the development of severe cardiovascular symptoms [130] . Berberine has also been shown to reduce total cholesterol and LDL-C in clinical trials [23, 60] . In studies in vitro, berberine alleviated palmitate-induced endothelial dysfunction via upregulation of endothelial nitric oxide synthase (eNOS) and downregulation of nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) [114] , an enzyme involved in age-associated cardiovascular dysfunction via oxidative stress and inflammation [150] ; it also inhibited HG-potentiated platelet aggregation [134] , suppressed HGinduced endothelial dysfunction and restored NO generation possibly via suppressing ectopic miR-133a expression and restoring peroxisome proliferator-activated receptor (PPAR) γ and AMPK signaling [44, 121, 123, 125, 126] . In another study, it reduced oxidized LDL-induced inflammatory responses in macrophages via AMPK activation and nuclear factor (NF)-B inhibition [135] . In addition, berberine protected cardiomyocytes from HG-induced damage and ischemia-reperfusion via enhancement of AMPK [116, 120, 124, 132] , PPARα [115] and PI3K-Akt-eNOS anti-apoptotic signaling pathways [116] . Berberine also attenuated cardiac fibrosis, possibly by reducing insulinlike growth factor (IGF)-1 receptor expression in cardiac fibroblasts [129] , and enhanced lipid metabolism in cardiomyocytes, possibly via protein kinase C inhibition [119, 127] ; it also suppressed cardiac arrhythmia by modulating K + and Ca 2+ [110, 113] . Furthermore, berberine may alleviate vascular dysfunction in diabetes by acting on adipose tissues. Berberine reduced body weight in HFD-fed mice [131, 136] , and induced fibroblast growth factor 21 (FGF21) and brain and muscle aryl hydrocarbon receptor nuclear translocator protein (Arnt)-like 1 expression in brown adipocytes in vivo and in vitro [136] , suggesting that berberine could modulate lipid metabolism in adipose tissues. Berberine also blocked adipogenesis in vitro [117, 118] , suppressed inflammatory (M1) macrophage polarization and aberrant extracellular matrix (ECM) deposition in adipose tissue of HFD-induced insulin-resistance model mice [128, 131] . In another study, it alleviated visceral white adipose tissue insulin resistance, possibly via sterol regulatory element-binding proteins (SREBPs) and PPARs [112] . Thus, berberine could alleviate diabetes-associated vascular dysfunctions via multiple pathways.
Liver dysfunction
As shown in Table 5 , berberine alleviated liver damage in STZ-and HFD-induced diabetic models [43, 95, 97, 105, 107, 108] , as well as in alloxan-induced diabetic model [98] . Treatment with berberine improved carbohydrate metabolism, and reduced oxidative stress, lipid peroxidation, inflammation and apoptotic cell death in the liver in STZ-induced diabetic model [43, 99, 107] . Similarly, in HFD-induced obesity models, insulin receptor and insulin receptor substrate (IRS)-1 induction, reduced inflammation [108] and hepatic mitochondrial protection were observed [101] .
There may be several mechanisms that support these outcomes: berberine could improve glucose metabolism in the liver by stimulating glucose uptake [109] , enhance glycolysis by restoring the expression and activity of the rate-limiting glycolytic enzyme [103] , while suppressing gluconeogenic enzymes [102, 109] , enhance lipid metabolism in the liver by modulating metabolic regulators such as human liver X receptor α (LXRα), SREBPs and PPARα [95] , and induce brownlike gene expression and high energy expenditure via FGF21 and SIRT1 signaling activation [106] . Furthermore, berberine could relieve hepatic inflammation possibly via AChE inhibition and restoration of ACh receptor-mediated anti-inflammatory signaling [104] . Thus, berberine has treatment effects that should combat diabetes-associated liver dysfunction and non-alcoholic fatty liver disease (NAFLD).
Kidney dysfunction
As shown in Table 6 , berberine ameliorated renal inflammation and injury in diabetic models [79, 83, 85, 86, 90, 96] . Underlying mechanisms include inhibition of kidney fibrosis via tumor growth factor (TGF)- signaling suppression and Nrf2 activity enhancement [76, 77, 80, 82, 86, 91, 93, 144] , suppression of HG-induced mesangial cell proliferation and hypertrophy via suppression of NF-B and AP-1 [81, 84, 90] , and attenuation of ECM accumulation [87] , possibly by restoring β-arrestin [88] and E prostanoid receptor 4 (EP4)-Gαs-cAMP signaling pathway [83, 85] . In addition, berberine directly protected podocytes from HG-induced injury in vitro [23, 94] , possibly by inhibiting podocyte apoptosis via AMPK-dependent autophagy induction [92] .
Intestinal metabolism, gut dysbiosis and systemic inflammation
As shown in Table 7 , berberine significantly affected intestinal microbiota and metabolism. Not only did berberine modulate intestinal glucose uptake by directly inhibiting digestion of disaccharides [68, 69] , but modulation of the gut microbiome may underlie these beneficial effects. For example, berberine increased Verrucomicrobia, which was associated with attenuation of atherosclerosis [130] , increased Akkermansia and restored intestinal barrier integrity [71, 74] , and restored short-chain fatty acid-producing Bacteroidetes in obese rodents [75] . It is postulated that berberine-mediated changes of gut microbiota, particularly the increase of short-chain fatty acidproducing bacteria [73, 75] , may contribute to the alleviation of inflammation, insulin resistance and obesity [70, 74] . Berberine also reduced the levels of plasma endotoxin and systemic inflammation in HFD-induced obesity model, possibly by reducing Escherichia coli and increasing Lactobacillus [108] .
Diabetic retinopathy
As shown in Table 8 , berberine protected retinal Müller cells from HG-and LDL-induced damage via enhancing AMPK signaling [65, 66] and prevented retinal endothelial injuries induced by HGactivated leukocytes [64] .
Diabetic neuropathy
Berberine ameliorated diabetic neuropathy [61] [62] [63] (Table 9 ), indicating the protection of the peripheral nervous system.
Additional evidence
As shown in Table 10 , both clinical and preclinical studies demonstrated that berberine can effectively restore normal glucose and lipid levels in the blood [22, [58] [59] [60] 67, 78, 122, 133] . Suggested underlying mechanisms include enhanced glucose uptake [100, 111, 143] , mitochondrial complex I inhibition [57] and AMPK signaling enhancement [57, 89] .
Discussion
Direct evidence supporting berberine's antidementia effects
AD is a metabolic disease with diabetes-associated molecular and biochemical features; dysfunctional insulin signaling in the brain may account for the structural and functional abnormalities in AD [151] . The expression levels of IGFs are significantly reduced in the AD brain, which was associated with reduced levels of IRS, IRS-associated PI3K and downstream serine/threonine-specific protein kinase Akt, as well as increased GSK3β activity [16] . As a master regulator of cellular energy metabolism, GSK3β is highly expressed in the adult hippocampus, particularly with age [152] . Its multiple functions include regulation of neural plasticity via neurogenesis, migration, axonal growth and synaptic plasticity [153] . The PI3K/Akt/GSK3β pathway plays crucial roles in neuroprotection and synaptic plasticity under various physiological and pathological circumstances [154, 155] . However, abnormally active GSK3β contributes to brain disorders including impairments in mood regulation, cognitive task performance [156] and hippocampal neurogenesis [157] . Importantly, tau protein is one of the targets of GSK3β [158] , and the PI3K/Akt/GSK3β pathway may play a key role in AD pathogenesis via enhanced phosphorylation of tau [158] . These data suggest that dysfunctional glucose metabolism may underlie AD development [16] . In fact, experimental diabetes induced by STZ causes cholinergic dysfunction and memory impairment [159] . Furthermore, intracerebral administration of STZ led to features characteristic of AD, including cognitive impairment and ACh homeostasis disturbances [160] , which could be alleviated by insulin sensitizers [15, 161] . Our literature survey indicated that berberine directly protects the brain cells against damages associated with dementia [27, 29, 32, 34, 39] , possibly via antioxidative and anti-inflammatory effects [28, 35, 37, 42] , and also by reducing A levels [31, 38] . Berberine was able to promote cognitive functions [38, 40] , through enhancing cholinergic neurotransmission [30, 33, 36, 41] . In addition, berberine alleviated diabetes-associated cognitive impairment [44, 45, 48, 49, [51] [52] [53] [54] [55] , possibly via the restoration of insulin signaling [50, 51] and reduction of oxidative stress and inflammation [43, 46, 47] in the brain. Although bioavailability of berberine is relatively low, it crosses the blood brain barrier and stably distributes in the brain tissue, compared to other organs [162] , suggesting that berberine could prevent dementia through direct actions in the brain. As a whole, berberine could protect brain functions via a number of mechanisms: neuroprotection [55, 62] , reducing oxidative stress [28, 35, 37, 43] , suppressing brain inflammation [51, 53] , reducing the generation of Aβ, hyperphosphorylated tau and APP [29, 31, 39, 146] , enhancing ACh signaling [28, 30, 33, 36, 41, 45] , and possibly reducing the accumulation of neurotoxic metabolites [32] , suggesting that berberine is an effective therapy against dementia including AD and VaD.
Antidementia effects of berberine via prevention of diabetes and comorbidities: an indirect mechanism
Evidence suggests strong associations between dementia and diabetes [7, 8, 15, 16] , which indicates that the risk of developing dementia could be reduced by a successful diabetes intervention. Berberine is a promising antidiabetic agent, as reported in previous review articles [20, 21, 24, 163] .
In the present work, we have updated how berberine acts against diabetes and its associated complications; we also discuss the potential of berberine as a treatment for diabetes-associated dementia.
Protection of pancreas
T2DM is characterized by hyperglycemia, associated with insulin resistance and insufficient insulin secretion due to pancreatic β-cell dysfunction. Our literature survey revealed that berberine protects pancreatic cells and restores insulin secretion by β-cells [56, [137] [138] [139] [140] [141] [142] . Brain insulin resistance is a key feature of AD and related dementias, and evidence suggesting the link between systemic and brain insulin resistance is growing [164, 165] . Thus, berberine may prevent dementia development by restoring pancreas functions and systemic insulin signaling.
Vascular protection
VaD is the second common form of dementia [166] . Although there are controversies surrounding the etiology of VaD, cerebral small vessel disease, associated with the breakdown of blood-brain barrier and perivascular inflammation, is likely the most common cause [166, 167] . The risk factors include dyslipidemia, hypertension and cardiovascular dysfunction [166] . High levels of LDL-C and low levels of HDL-C increase the risk for carotid atherosclerosis and coronary artery disease, which may result in cerebral hypoperfusion or embolism, leading to cognitive dysfunctions [166, 168] . In addition, cardiovascular disease-associated oxidative stress and lipid peroxidation, due to low levels of antioxidants, are thought to cause damage to brain cells [166, 169, 170] . Dyslipidemia and hypertension, associated with obesity and insulin resistance, are often present in the prediabetic period of T2DM, which may account for the comorbidity of cardiovascular disease and diabetes [171, 172] . T2DM dyslipidemia is characterized by increased triglycerides and LDL-C and reduced HDL-C levels [173, 174] . Evidence suggests that cholesterol-lowering therapy reduces cardiovascular risk in diabetic patients [174, 175] ; however, low HDL-C likely contributes to diabetes as well as cardiovascular disease [173] . Thus, lowering total cholesterol while restoring HDL-C would be most beneficial for treating diabetes-associated cardiovascular diseases and VaD. On the other hand, studies have suggested that impaired endothelial dysfunctions and platelet hyperaggregation, causing microvasculature injuries, are the main causes of increased morbidity and mortality of T2DM [176] . Impaired eNOS activity and hypercoagulable states associated with atherosclerosis and vascular dysfunction are observed in the vascular system of diabetes and associated MetS [177, 178] . In addition, altered glucose metabolism and glucose overload in cardiomyocytes promote oxidative stress and accumulation of advanced glycation end-products, subsequently causing apoptosis and cardiac dysfunction [179, 180] . Furthermore, pro-and antiinflammatory mediators released from perivascular adipose tissue are involved in the development of atherosclerosis [181] , suggesting that adipocytes may play a key role in diabetes-associated cardiovascular dysfunctions. The results demonstrated that berberine could protect cardiovascular functions by reducing the risk of hypertension [123, 126] and coagulation [134] , attenuating cardiac hypertrophy [115, 129, 132] and cardiac arrhythmias [110, 113] , and inhibiting potential cardiovascular damages associated with dyslipidemia [74, 114, 116, [119] [120] [121] 124, 125, 130, 135, 136] . In addition, berberine reduced obesity and cardiovascular risk at least in part via modulating adipocyte populations and inflammatory state in the adipose tissues [112, 117, 118, 128, 131] . Taken together, berberine could promote vascular functions, thereby preventing the development of VaD.
Liver protection
The liver plays a vital role in energy metabolism. Hepatic insulin signaling is essential for the maintenance of carbohydrate and lipid homeostasis, and the liver plays a major role in the development of insulin resistance and T2DM [182] . NAFLD and T2DM are common conditions associated with insulin resistance and vascular dysfunctions, and NAFLD prevalence is high in prediabetic and obese populations [182] [183] [184] . Evidence suggests the link between T2DM or NAFLD and insulin resistance in the brain [185, 186] , and that hepatic ceramide, a neurotoxin that causes insulin resistance, may mediate brain insulin resistance and neurodegeneration in T2DM and NAFLD [187] . In fact, NAFLD induces signs of AD in wild-type mice and accelerates pathological signs of dementia in an AD model [188] . Thus, the liver could be an important target in the prevention of AD and MetS-associated dementia.
The results indicated that berberine protects liver functions [102, 103, 105, 108] through restoring glucose and lipid metabolism [95, 101, [104] [105] [106] 109] and suppressing inflammation and oxidative stress [43, 97, 98, 104, 107] . Collectively, berberine could prevent dementia through the restoration of liver functions.
Kidney protection
Diabetic nephropathy is a major complication and a common cause for chronic kidney disease (CKD) [189] , which is significantly associated with cognitive impairment [190, 191] . Between 16% and 38% of dialysis patients have cognitive impairment, which is approximately threefold higher than age-matched controls [192] ; VaD seems more prominent in CKD than other types of dementias, such as AD [193] . Dialysis patients tend to have reduced total brain and subcortical volumes and perform poorly in attention/information processing speed and executive function [194] . Glomerular mesangial cell hypertrophy and podocyte loss are the major pathological changes of diabetic nephropathy [195] , and injuries to podocytes associated with dysregulation of AMPK play a key role in diabetic nephropathy [195] . Indeed, deficient autophagy caused by AMPK dysregulation can induce podocyte loss and glomerulosclerosis [196] , pointing to the importance of AMPK signaling in treating diabetic nephropathy and associated cognitive impairment. This study revealed that berberine prevents diabetic nephropathy [79, 83, 85, 86, 90, 96] . Potential mechanisms include podocyte protection [92, 94] via AMPK activation [92] , and inhibition of renal fibrosis and inflammation [76, 77, [80] [81] [82] 84, 86, 91, 93, 144] via TGF-β signaling suppression [80, 82, 84, 86, 91, 93, 144] . Considering that TGF-β promotes kidney cell injury via inhibition of AMPK [197] , it is probable that berberine ameliorated kidney fibrosis by counteracting TGF-β signaling by restoring AMPK activity. Collectively, berberine could prevent diabetic nephropathy via suppression of hypertrophy and podocyte protection, thereby alleviating cognitive impairment associated with kidney dysfunction.
Restoration of gut microbiota and intestinal metabolism
Among 100 trillion micro-organisms residing in human body, the vast majority are in the intestinal tract [198] . Growing evidence indicates that a critical role of the gut microbiota is as a host metabolism regulator [199] , and the imbalance of gut microbiota (gut dysbiosis) has been linked to various metabolic disorders including diabetes [200, 201] . Changes in the intestinal ecosystem could alter intestinal permeability, cause inflammation and modulate bile acid metabolism, short-chain fatty acids and other metabolites, contributing to insulin resistance [202] and progression of diabetes-associated conditions [203, 204] . In fact, links between the gut microbiota and NAFLD [205] , cardiovascular disease [206] or CKD have been suggested [207] . Furthermore, the intestinal microbiota likely takes part in bidirectional communication between the gut and the brain [208] . Thus, gut microbiota provides a promising therapeutic target to alleviate diabetes-associated dementia.
Our literature review indicated that berberine influences body metabolism and suppresses systemic inflammation via modulation of gut microbiota [70, 74, 75, 108, 130] . Of note, berberine-containing plants, such as Coptis and Phellodendron spp., have been used traditionally to treat diarrhea, as well as to promote intestinal health [209] , and berberine's antimicrobial activity against various pathogenic bacteria is well known [210] . Due to poor absorption of berberine, it is reasonable to speculate that antidiabetic action of berberine is at least in part mediated via effects on the gut microbiota [210] .
Retinal protection
Evidence suggests that the status of retinal neuronal structure and vasculature can reflect that of the cerebral nervous system [211] . Our literature survey revealed that berberine could prevent diabetic retinopathy [64] [65] [66] . Although the mechanistic link between retinal injuries and cognitive dysfunction is not clear, these data support that berberine could prevent diabetes-associated damages to the neuronal network in the central nervous system, including retina.
Enhancing glucose and lipid metabolism
In addition to preventing diabetes-associated tissue damages, berberine may reduce the risk of MetS development by enhancing glucose and lipid metabolism. However, despite berberine's wellestablished antihyperglycemic and antihyperlipidemic activities, the underlying molecular mechanisms are less clear. One suggested mechanism is that berberine lowers blood glucose by enhancing AMPK activity in peripheral tissues [89, 212] . AMPK is a serine/threonine kinase that is activated in response to adenosine triphosphate (ATP) depletion; its action is to restore cellular ATP levels and energy supply, acting as an energy sensor and a metabolic master regulator [213] . Enhanced AMPK activity, upon berberine-treatment, has been observed in several studies using diabetic animal models [63, 65, 102, 128] as well as in vitro models [57, 65, 66, 114, 128, 132, 135] . However, it is not clear whether the glucose-lowering effect is indeed mediated by AMPK activation [57] . Recent studies suggest that berberine's glucose-lowering effects could operate through a variety of mechanisms, including: enhanced cellular glucose uptake and consumption [57, 59, 100, 111, 143] via p38 MAP kinase and ERK signaling [111] ; protein-tyrosine phosphatase 1B (PTP1B) inhibition, thereby mimicking insulin signaling [100, 133] ; and insulin receptor sensitization to low-dose insulin [22] . However, this mechanism is likely independent of AMPK [57, 111] . In addition, berberine is a potent mitochondrial complex I inhibitor and can affect glucose consumption through reduction of ATP generation from mitochondrial oxidative phosphorylation and consequent enhancement of glycolytic activity [57] . Thus, berberine might act as antihyperglycemic, through multiple targets including mitochondrial complex I, while AMPK activation might benefit different aspects of diabetic complications, such as suppression of inflammation [135] and hepatic gluconeogenesis [102] . On the other hand, the antihyperlipidemic activity of berberine could be explained by induction of brown adipocytes via FGF21 signaling [106, 136, 214] , possibly through AMPK [136] .
Limitations and future perspectives
In summary, evidence from numerous studies supports the effectiveness of berberine as a dementia intervention via direct neuroprotection in the brain as well as indirect mechanisms through the prevention of diabetes-associated comorbidities (Fig. 2) . Growing evidence suggests that both AD and VaD are associated with diabetes [7, 8, 15, 16, 215, 216] , and the risk of dementia development could be reduced by successful intervention of diabetes and its comorbidities [13, 215, 217] . As summarized in previous review articles, berberine is a promising antidiabetic agent [20, 21, 24, 163] , and preclinical evidence suggests that berberine has neuroprotective effects [25, [218] [219] [220] [221] . Here, we collectively evaluated the effectiveness of berberine as a treatment for diabetes-associated dementia by two database searches (Fig. 1) . The advantage of this study is that it clarified direct and indirect evidence by categorizing the publications into three groups: antidementia effects that has no obvious association with diabetes (Table 1) , effects on diabetes-associated dementia ( Table 2) and antidiabetic effects (Tables 3 to 10 ). The limitations of the study include the fact that most of the articles reviewed in this report are preclinical studies using in vivo and/or in vitro models, thus future research must focus on clinical significance. In addition, it is unknown whether berberine, as a constituent of traditional medicine, rather than as an isolate, could exert the same effectiveness. Berberine is a natural alkaloid found in various medicinal plant species [36, [222] [223] [224] [225] [226] [227] [228] [229] (Table 11 ). These medicinal plants could be useful in the prevention of dementia associated with metabolic disorders. Using locally available plants may have advantages over isolates, reducing the cost and possibly providing additional therapeutic and nutritional benefits derived from the plants. In fact, some of those plants, including B. vulgaris, Coptis spp. and P. amurense have been used in traditional medicines to treat cardiovascular diseases, diabetes and dementia [230] [231] [232] [233] . However, those plants contain berberine at different levels, and the variability of berberine contents within the same species, depending on the geographical origins and plant parts used, is nonnegligible [222, 228] . Furthermore, those plants and their extracts contain numerous other constituents, which might produce synergistic effects, either enhancing or reducing the efficacy of berberine. Further research is needed to assess the effectiveness and safety of berberine-containing medicinal plants in the prevention of dementia associated with metabolic dysfunctions. 
